Abstracts tagged "Vasculitis"

Abstract Number: 2191 • ACR Convergence 2024
Optimizing Inpatient Kawasaki Disease Care
Audrea Chen¹, Beth Gamulka², Macarena Palomer³ and Rae Yeung⁴, ¹The Hospital for Sick Children, Burnaby, BC, Canada, ²The Hospital for Sick Children, Toronto, ³The Hospital for Sick Children, Toronto, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Kawasaki Disease (KD), an acute pediatric vasculitis, requires inpatient management to prevent coronary artery disease. The Hospital for Sick Children (SickKids) sees about 100…
Abstract Number: 2506 • ACR Convergence 2024
THP1-derived Macrophage Polarization in Takayasu Arteritis – Impact of Disease Status and Therapy
João Paulo dos Santos¹, Cristina Orikaza¹, Mariana Aguiar², Gerson Keppeke³ and Alexandre de Souza⁴, ¹Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ²Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ³Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, ⁴UNIFESP-EPM, São Paulo, SP, Brazil
Background/Purpose: Macrophages play an important role in the pathophysiology of Takayasu arteritis (TAK) as granulomatous inflammation is typically found in affected arteries. The expression of…
Abstract Number: 2648 • ACR Convergence 2024
Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging
Vicente Aldasoro¹, Vicky Betech-Antar², Santos Castañeda³, Eugenio De Miguel⁴, Juan José Rosales⁵ and Maria Jose García Velloso⁵, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Clinica Universidad de Navarra, Pamplona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Clínica Universidad de Navarra, Pamplona, Spain
Background/Purpose: The aim of this study is to analyse the diagnostic value of the delay images at 180 minutes in positron emission tomography (PET) performed in…
Abstract Number: 0743 • ACR Convergence 2024
Higher Baseline FDG Musculoskeletal Uptake at PET/CT Is Associated with a Higher Remission Rate in Polymyalgia Rheumatica: A Retrospective 3-year Observational Study
Elvis Hysa¹, Dario Camellino², Cristina Bernini³, Paolo Vittoriano Clini⁴, Matteo Bauckneht⁵, silvia Morbelli⁶, Gianmario Sambuceti⁵, Emanuele Gotelli⁷, Alberto Sulli⁸, Maurizio Cutolo⁷ and Marco Amedeo Cimmino¹, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²Division of Rheumatology, Local Health Trust 3, Genoa, Italy, ³Emergency Medicine Department, San Martino Polyclinic Hospital, Genoa, Italy,, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Nuclear Medicine Unit and Department of Health Sciences, University of Genova, Genoa, Italy, Genoa, Italy, ⁶University of Torino, Torino, Italy, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ⁸Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases characterized by increased musculoskeletal and vascular uptakes of 18-Fluorodeoxyglucose (18F-FDG) at positron…
Abstract Number: 0768 • ACR Convergence 2024
Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review
Shelley Fritz¹, Angela Degrassi², Kelly Gavigan², Ruohan Hong³, Santiago Munoz Perez², Esteban Rivera⁴, Erik Stone⁵, Laura Stradford⁶, Ambika Vartak², Anne Sydor² and Shilpa Venkatachalam³, ¹Global Healthy Living Foundation, Kalaheo, HI, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Long Island City, NY, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: This systematic literature review on polymyalgia rheumatica (PMR) and PMR with giant cell arteritis (GCA) evaluates existing literature on disease burden, management, and treatment…
Abstract Number: 1601 • ACR Convergence 2024
Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023
Lynn Fussner¹, Christian Pagnoux², David Cuthbertson³, Thomas Corbridge⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Rennie Rhee⁸, Philip Seo¹¹, Anat Shavit¹², Jared Silver¹³, Ulrich Specks¹⁴, Kenneth Warrington¹⁴, Michael Wechsler¹⁵ and Peter Merkel⁸, and for the Vasculitis Clinical Research Consortium, ¹The Ohio State University, Columbus, OH, ²Mount Sinai Hospital, Toronto, ON, Canada, ³University of South Florida, Tampa, FL, ⁴US Value Evidence and Outcomes, GSK, Durham, NC, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Johns Hopkins University, Baltimore, MD, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³US Medical Affairs - Respiratory, GSK, Durham, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵National Jewish Health, Denver, CO
Background/Purpose: The emergence of biologic therapies targeting eosinophils via the IL-5 pathway provided new options for treatment in eosinophilic granulomatosis with polyangiitis (EGPA). There has…
Abstract Number: 1634 • ACR Convergence 2024
A Lexicon of Signs and Symptoms of Giant Cell Arteritis: An International Expert Consensus
Medha Soowamber¹, Milena Bond², Carol Langford³, Zahi Touma¹, Catalina Sanchez Alvarez⁴, Andy Abril⁵, Sibel Aydin⁶, FRANK HARTMUT DR. BUTTGEREIT⁷, Dario Camellino⁸, Maria Cid⁹, Peter Grayson¹⁰, Bernhard Hellmich¹¹, William Lichliter¹², Tanaz Kermani¹³, Nader Khalidi¹⁴, Sarah Mackie¹⁵, Eric Matteson¹⁶, Mehrdad Maz¹⁷, Peter Merkel¹⁸, Paul Monach¹⁹, Lorna Neill²⁰, Cristina Ponte²¹, Carlo Salvarani²², Wolfgang Schmidt²³, Peter Villiger²⁴, Kenneth Warrington²⁵, Madeline Whitlock²⁶, Sofia Ramiro²⁷ and Christian Dejaco²⁸, ¹University of Toronto, Toronto, ON, Canada, ²Unit of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsus Medical University, Bruneck, Italy, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Florida, Gainesville, FL, ⁵Mayo Clinic, Ponte Vedra Beach, FL, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸La Colletta hospital, Arenzano, Italy, ⁹Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹¹Medius Kliniken, Kirchheim unter Teck, Germany, ¹²patient, Vienna, Austria, ¹³University of California Los Angeles, Santa Monica, CA, ¹⁴McMaster University, Hamilton, ON, Canada, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷The University of Kansas Medical Center, Kansas City, KS, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹VA Boston Healthcare System, Boston, MA, ²⁰Patient Charity Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Nethy Bridge, United Kingdom, ²¹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal, ²²Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ²³Immanuel Krankenhaus Berlin, Berlin, Germany, ²⁴Medical Center Monbijou, Bern, Switzerland, ²⁵Mayo Clinic, Rochester, MN, ²⁶Southend University Hospital, Southend, United Kingdom, ²⁷Leiden University Medical Center, Bunde, Netherlands, ²⁸Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: The lack of standardized definitions and descriptors for clinical manifestations of giant cell arteritis (GCA) leads to variable interpretations of findings in clinical practice…
Abstract Number: 2479 • ACR Convergence 2024
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Michael E Wechsler¹, Anna Kovalszki², Jared Silver³, Brian Stone⁴, Lior Seluk⁵, Lynn Huynh⁶, Wilson da Costa Junior⁶, Mingchen Ye⁶, Jeremiah Hwee⁷, Mei Sheng Duh⁶, William McCann⁴ and Amy G. Edgecomb⁸, ¹Department of Medicine, National Jewish Health, Denver, CO, ²Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³US Medical Affairs - Respiratory, GSK, Durham, ⁴Allergy Partners, Asheville, NC, ⁵Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, ⁶Analysis Group, Boston, MA, ⁷Value Evidence and Outcomes, GSK, Mississauga, Canada, ⁸US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
Abstract Number: 2509 • ACR Convergence 2024
Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
Benjamin Turturice¹, Alice Fike¹, Bhavisha Patel², Emma Groarke², Karyssa Stonick¹, Shanni Liu¹, Wendy Goodspeed¹, Kaitlin Quinn¹, Neal Young² and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS is a multisystem autoinflammatory disorder due to somatic mutations in UBA1. The disease is characterized by ineffective hematopoiesis with increased risk of transfusion…
Abstract Number: 2649 • ACR Convergence 2024
Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts
Shubhasree Banerjee¹, Carol McAlear², Peter Merkel³, Peter Grayson⁴ and Marcela Ferrada⁵, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁵University of Maryland, Baltimore, MD
Background/Purpose: Lack of awareness and disease heterogeneity are common factors associated with diagnosis delay in patients with Relapsing polychondriytis (RP). Using latent class analysis (LCA),…
Abstract Number: 0236 • ACR Convergence 2023
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
orrin Troum¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹University of Southern California Keck School of Medicine and Providence Saint John's Health Center, Santa Monica, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is associated with high comorbidity, including cardiovascular (CV), metabolic, and renal disease,1 with even higher burden in uncontrolled gout patients (pts).2 CV (myocardial…
Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Jose Luis Martin-Varillas³, Carmen Alvarez Reguera¹, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Raul Fernandez¹, Ivan Ferraz Amaro⁶, Jose Luis Hernandez¹ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital de Sierrallana, Santander, Spain, ⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
Abstract Number: 0853 • ACR Convergence 2023
Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
Shruthi Srivatsan¹, Zachary Williams¹, Claire Cook¹, Xiaoqing Fu¹, Naomi Patel¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-to-medium vessel vasculitis associated with substantial morbidity and mortality, in part due to glucocorticoid exposure. Avacopan, an oral C5a…
Abstract Number: 1546 • ACR Convergence 2023
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Ricardo Blanco¹, Iñigo Rúa-Figueroa², Roser Solans³, Maria C Cid⁴, Marina Blanco⁵, Ismael Garcia Moguel⁶, Francisco Perez Grimaldi⁷, Ana Noblejas⁸, Moises Labrador³, Cristian Domingo⁹, Georgina espigol¹⁰, Fernando Sanchez Toril¹¹, Francisco Ortiz-Sanjuán¹², Ebymar Arismendi¹³ and Jose María Alvaro-Gracias¹⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ³Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, ⁶Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, ⁷Pneumology Department, H. University of Jerez, Cádiz, Spain, ⁸Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, ⁹Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁰Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, ¹¹Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, ¹²Hospital Universitario y Politécnico La Fe, Valencia, Spain, ¹³Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…
Abstract Number: 1650 • ACR Convergence 2023
Optic Nerve Sheath Measurement as a Disease Activity Biomarker in Giant Cell Arteritis
Carolyn Ross¹, Stephanie Ducharme-Benard², Samer Hussein³, Rosalie-Selene Meunier³, Christian Pagnoux⁴ and Jean-Paul Makhzoum¹, ¹Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Recently, optic nerve sheath (ONS) enhancement using contrast-enhanced magnetic resonance imaging of the brain and orbits was observed in most patients with biopsy-proven GCA.…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].